A CK2-dependent mechanism for degradation of the PML tumor suppressor

被引:251
|
作者
Scaglioni, Pier Paolo
Yung, Thomas M.
Cai, Lu Fan
Erdjument-Bromage, Hediye
Kaufman, Andrew J.
Singh, Bhuvanesh
Teruya-Feldstein, Julie
Tempst, Paul
Pandolfi, Pier Paolo
机构
[1] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, Sloan Kettering Inst, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Program Mol Biol, Sloan Kettering Inst, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
关键词
D O I
10.1016/j.cell.2006.05.041
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The PML tumor suppressor controls key pathways for growth suppression, induction of apoptosis, and cellular senescence. PML loss occurs frequently in human tumors through unknown posttranslational mechanisms. Casein kinase 2 (CK2) is oncogenic and frequently upregulated in human tumors. Here we show that CK2 regulates PML protein levels by promoting its ubiquitin-mediated degradation dependent on direct phosphorylation at Ser517. Consequently, PML mutants that are resistant to CK2 phosphorylation display increased tumor-suppressive functions. In a faithful mouse model of lung cancer, we demonstrate that Pml inactivation leads to increased tumorigenesis. Furthermore, CK2 pharmacological inhibition enhances the PML tumor-suppressive property in vivo. Importantly, we found an inverse correlation between CK2 kinase activity and PML protein levels in human lung cancer-derived cell lines and primary specimens. These data identify a key posttranslational mechanism that controls PML protein levels and provide therapeutic means toward PML restoration through CK2 inhibition.
引用
收藏
页码:269 / 283
页数:15
相关论文
共 50 条
  • [1] A CK2-dependent mechanism for PML degradation upon cellular and oncogenic stress.
    Scaglioni, Pier P.
    Yung, Thomas M.
    Cai, Lu F.
    Erdjument-Bromage, Hediye
    Kaufman, Andrew J.
    Singh, Bhuvanesh
    Teruya-Feldstein, Julie
    Tempst, Paul
    Pandolfi, Pier Paolo
    BLOOD, 2006, 108 (11) : 414A - 414A
  • [2] CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor
    Scaglioni, P. P.
    Yung, T. M.
    Choi, S. C.
    Baldini, C.
    Konstantinidou, G.
    Pandolfi, P. P.
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2008, 316 (1-2) : 149 - 154
  • [3] CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor
    P. P. Scaglioni
    T. M. Yung
    S. C. Choi
    C. Baldini
    G. Konstantinidou
    P. P. Pandolfi
    Molecular and Cellular Biochemistry, 2008, 316 : 149 - 154
  • [4] CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor
    P. P. Scaglioni
    T. M. Yung
    S. Choi
    C. Baldini
    G. Konstantinidou
    P. P. Pandolfi
    Molecular and Cellular Biochemistry, 2009, 327 : 279 - 279
  • [5] A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway
    Zheng, Ying
    Qin, Hongwei
    Frank, Stuart J.
    Deng, Luqin
    Litchfield, David W.
    Tefferi, Ayalew
    Pardanani, Animesh
    Lin, Fang-Tsyr
    Li, Jingzhi
    Sha, Bingdong
    Benveniste, Etty N.
    BLOOD, 2011, 118 (01) : 156 - 166
  • [6] CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor (vol 316, pg 149, 2008)
    Scaglioni, P. P.
    Yung, T. M.
    Choi, S.
    Baldini, C.
    Konstantinidou, G.
    Pandolfi, P. P.
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2009, 327 (1-2) : 279 - 279
  • [7] Is PML a tumor suppressor?
    Mazza, Massimiliano
    Pelicci, Pier Giuseppe
    FRONTIERS IN ONCOLOGY, 2013, 3
  • [8] PROTEASOMAL DEGRADATION OF THE TUMOR SUPPRESSOR PML SUPPORTS HCC DEVELOPMENT
    Kretschmann, Gina
    Beilfuss, Anja
    Sowa, Jan-Peter
    Biesterfeld, Stefan
    Ertle, Judith M.
    Gerken, Guido
    Canbay, Ali
    Galle, Peter R.
    Herzer, Kerstin
    HEPATOLOGY, 2010, 52 (04) : 597A - 597A
  • [9] HCC DEVELOPMENT IS SUPPORTED BY PROTEASOMAL DEGRADATION OF THE TUMOR SUPPRESSOR PML
    Straub, K.
    Simon, F.
    Khairzada, K.
    Beilfuss, A.
    Gerken, G.
    Canbay, A.
    Paul, A.
    Weber, F.
    Kerstin, H.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S445 - S445
  • [10] Chimeric peptides as modulators of CK2-dependent signaling: Mechanism of action and off-target effects
    Zanin, Sofia
    Sandre, Michele
    Cozza, Giorgio
    Ottaviani, Daniele
    Marin, Oriano
    Pinna, Lorenzo A.
    Ruzzene, Maria
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2015, 1854 (10): : 1694 - 1707